WhiteCoat AI’s Post

Stay up to date with the newest developments in anticoagulation for Atrial Fibrillation. We assembled comprehensive resources on Guidance, Therapeutic Management, and Risk Assessment, highlighting examples of clinical excellence. Explore our rapid resources, including checklists and decision-making tools, designed to support healthcare professionals. Discover more and enhance your practice during #AFibAwareness: https://bit.ly/3XvUDLI International Society on Thrombosis and Haemostasis (ISTH) National Blood Clot Alliance StopAfib.org

Discussion about evidence standards and evidence needs from different perspectives in the patient journey at the World Orphan Drug Congress Europe. HTA bodies have high evidence tresholds, but for many rare and ultra rare diseases gold standard RCTs are not possible or take unacceptable long time. Pragmatic evidence generation via case reports, registries, natural disease history studies, and other should be acceptable and be linked to payment models to get timely access for patients in need. Patients and caregivers voice should be an integral part of evidence generation and presentation of the data in HTA discussions and assessments.

📑 The article “A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative” co-authored by the EHC expert Manon Degenaar-Dujardin is published and now available in the Haemophilia Journal! A core outcome set (COS)—a minimum set of agreed-upon outcomes to be used in every clinical trial for a given condition—provides guidance on which outcomes are most important to measure to ensure necessary data is collected for a variety of stakeholders and enable comparison across products and trials. The developed coreVWD COS represents a consensus list of outcomes for clinical trials for both factor and non-factor VWD therapies. These outcomes will be useful across the lifecycle of a product, from clinical development through regulatory and market access phases and into patient-provider decision-making. Read the article to know more: https://lnkd.in/et6Ue2uj

Do you have patients that suffer from a chronic disease? Clinical trials play an important role in developing treatments for chronic diseases and are becoming more accessible and inclusive through innovations such as decentralized features and pragmatic designs. This #ChronicDiseaseDay, learn about the FDA's CDER Center for Clinical Trial Innovation (C3TI), a central hub that supports innovative approaches to clinical trials to improve the efficiency of drug development for chronic diseases and other conditions. Learn more: https://lnkd.in/gwmKUxsj

Our open access journal IPIP received its first impact factor this year - a mighty 1.8! Not bad for a first go. Dr Vanesa Anton-Vazquez sat down to talk with us about experience of publishing with IPIP, and her work on the clinical, microbiological characteristics and predictors of mortality in patients with CPE bloodstream infections. "The reaction to our paper has been very encouraging, sparking discussions on the importance of early and effective empirical antibiotic therapy and its impact on patient outcomes. We hope that our findings will prompt improvements in timely diagnosis, given the urgent need to reduce mortality rates in patients with CPE-BSIs." Read the interview here: https://ow.ly/THzZ50SzHva Read Dr Anton-Vazquez's work here: https://lnkd.in/eaqBdeva

Elixir Medical Corporation Reports the Data from INFINITY-SWEDEHEART Study of DynamX Coronary Bioadaptor System for Coronary Artery Disease #elixirmedical #dynamxcoronarybioadaptorsystem #coronaryarterydisease #medtech #infinityswedeheart #targetvesselfailure #targetlesionfailure #ischemicheartdisease

📄 𝐑𝐢𝐛𝐨𝐡𝐲𝐚𝐥 𝐃𝐫𝐨𝐩𝐬: 𝐓𝐡𝐞 𝐍𝐞𝐰 𝐏𝐚𝐩𝐞𝐫 We are proud to announce that the latest study on our Ribohyal drops, based on our NCE Ribohyal (Har®, 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐻𝑦𝑎𝑙𝑢𝑟𝑜𝑛𝑖𝑐 𝐴𝑐𝑖𝑑), has just been accepted for publication in the Heliyon Journal 🎯 The study evaluated the 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐨𝐟 𝐑𝐢𝐛𝐨𝐡𝐲𝐚𝐥 compared to hyaluronic acid eye drops in patients with dry eye disease, confirming the advantages of our NCE: ✔️ OSDI and Osmolarity showed better improvements in the Ribohyal group ✔️Among the OSDI parameters, photophobia was more effectively improved in the Ribohyal group ✔️ The presence of Riboflavin in the NCE can improve the recovery and protection in DED patients ✔️ Ribohyal effectively reduced DED symptoms and improved photophobia within two hours of instillation, lasting up to 8 weeks. Stay tuned for more information #DryEyeDisease #MedicalResearch #EyeCare

Exciting to see the following quote from FDA’s Kevin Bugin - “C3TI supports innovative clinical trial approaches to enhance the efficiency of drug development for chronic diseases and beyond.”

Transplant recipients face heightened risks of complications, including pneumonia, a frequent yet challenging condition to manage in immunocompromised patients. Early symptoms may be subtle, underscoring the need for prompt diagnosis and low-threshold empiric therapy. Isolated upper airway pathogens may not always cause pneumonia. Viruses like CMV can act as co-pathogens, influencing infection severity and graft function. Tailored therapy considers antimicrobial resistance, drug interactions, and immunosuppression adjustments. A structured approach ensures early recognition and treatment, safeguarding graft function and patient outcomes. Read more: https://hubs.la/Q02YTrqV0 #TransplantCare #Pneumonia #Immunosuppression #CMV #InfectiousDiseases #SolidOrganTransplant #StemCellTransplant #AntimicrobialResistance #Radiology #EarlyDiagnosis

Test Your Clinical Skills with MedOne Education's Case of the Month! Expand your expertise, one case at a time! This month, we explore Listeria monocytogenes, a facultative intracellular gram-positive rod. Learn how infections from contaminated food are transmitted and how this pathogen differs from most. Gain invaluable insights and sharpen your diagnostic skills! https://lnkd.in/gQXvdyby #NeonatalMeningitis #MedicalCaseStudy #PathogenReview #MedicalEducation #InfectiousDiseases #ClinicalOutcomes #MedStudentLife #HealthcareProfessionals #MedOne #ThiemeIndia #MedicalKnowledge #HealthcareEducation